MagSense® Technology
A Medical Imaging Breakthrough
MagSense® technology is a new functional imaging agent that holds the promise of being more sensitive
and safer for detecting cancers and other critical diseases.
How is MagSense® technology better than other imaging methods?
MagSense® Advantages
More accurate
The bio-functionalized nanoparticles detect actual tumor cells not just an anatomically suspicious lesion.
Safer for Patients
The iron oxide nanoparticles are made of bio-safe materials, require no radiation and the core component iron is used up by the body. It has the potential to eliminate unnecessary biopsy procedures.
Accessible
The MagSense® imaging agent works with mainstream clinical MRI scanners as part of standard clinical diagnostic workflow.
MagSense® Nanoparticles
Magnetite Nanoparticle Core
Uniformly sized superparamagnetic Fe3O4.
Protective Polymer Coating
Monolayer provides stability in aqueous suspensions.
Stealth Coating – PolyEthylene Glycol
Minimizes opsonization in biological applications.
Targeting Moieties
Antibodies, peptides or cancer specific small molecules provides specificity for targeting tumor cells.
How does MagSense® imaging technology work?
MagSense® nanoparticles result in unique and differentiable image contrast when imaged by MRI.
Bio-safe magnetic nanoparticles are attracted to the tumor and detected.
Patients are given a low dose injection of the nanoparticle imaging agent.
Targeting molecules affixed to the nanoparticles, ensure high specificity for the cancer, and cause the nanoparticles to find and bind to tumor cells.
Only the tumor attached particles are detectable by magnetic sensors of Magnetic Relaxometry. With MRI, tumor bound MagSense particles result in unique image contrast, well differentiated from nontumor containing tissue contrast.
The tiny nanoparticles are cleared by the body through the liver with the iron core being “repurposed” to produce ferratin used in hemoglobin production
How will it change cancer detection?
Most cancers are asymptomatic, growing unnoticed and undetected until the tumor has grown large enough to cause identifiable symptoms. Imaging methods like X-rays, ultrasound, and conventional MRI methods detect anatomical abnormalities and hence are only useful in detecting later-stage cancers when the tumor has grown to be tens- or hundreds of millions of cells. As a result, conventional cancer treatments start after cancer has grown large and has developed defensive mechanisms or has already progressed and spread.
Additionally, because current methods do not detect cancer cells and hence cannot distinguish benign tumors from true cancers, invasive biopsy procedures are needed to confirm if it is truly cancer, often resulting in needless patient anxiety.
A safer, non-invasive solution
MagSense® nanoparticles work within current standard cancer diagnosis and routine clinical assessment protocols.
MagSense® Applications
Breast Cancer
Breast cancer is the second leading cause of cancer related deaths in women and the second most common cancer diagnosed in women.
Prostate Cancer
Prostate cancer is the second most frequent form of cancer found in men with 1 in 7 men being diagnosed with prostate cancer during their lifetime.
Ovarian Cancer
Only about 20% of ovarian cancers are found at an early stage because ovarian cancer is largely asymptomatic.
Latest News
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Imagion presents MagSense® interim study results at breast cancer meeting
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
Imagion to Present Prostate Cancer Research Data at WMIC 2022
Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion Biosystems
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.